Haemonetics CORP Form 4 insider transactions

Haemonetics Corp's EVP, Chief Commercial Officer Roy Galvin, filed an amended Form 4 to correct previously reported Restricted Stock Units and Non-qualified Stock Options.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, was awarded 3,195 restricted stock units on June 5, 2025, as part of the company's long-term incentive plan.

Haemonetics Corporation's VP and Chief Accounting Officer, Maryanne Maunsell Farris, was granted 2,662 restricted stock units as part of the company's long-term incentive plan.

Michelle L. Basil, EVP and General Counsel of Haemonetics Corp, reported the acquisition of 15,554 shares from a performance share unit award and the subsequent disposition of 7,469 shares for tax obligations.

Haemonetics Corp's President and CEO, Christopher Simon, acquired 66,666 shares from a performance share unit award and simultaneously disposed of 26,234 shares to cover tax obligations on May 30, 2025.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp (HAE), reported the vesting of performance share units (PSUs) and a subsequent disposition of shares for tax obligations.

Haemonetics Corporation's EVP and Chief Financial Officer, James D'Arecca, reported the acquisition of 12,221 common shares from vested performance share units and the disposition of 5,864 shares for tax obligations on May 30, 2025.

Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp, reports acquisition of shares and options.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports acquisition of common stock and stock options.

Frank Chan, EVP and COO of Haemonetics, reports the acquisition of 5,689 restricted stock units and 12,317 stock options.

Roy Galvin, President, Global Plasma & BC at Haemonetics Corp, reports the acquisition of common stock and stock options.

Michelle Basil, EVP and General Counsel of Haemonetics, reports the acquisition of restricted stock units and stock options.

James D'Arecca, EVP and CFO of Haemonetics, reports the acquisition of restricted stock units and stock options.

Christopher Simon, President & CEO of Haemonetics Corp, reports the acquisition of restricted stock units and stock options.

Michelle Basil, EVP and General Counsel of Haemonetics Corp, reported disposing of shares to cover tax obligations related to vesting restricted stock units.

James D'Arecca, EVP and Chief Financial Officer of Haemonetics, reported disposing of common stock to cover tax obligations related to vesting restricted stock units.

Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Roy Galvin, President of Global Plasma & BC at Haemonetics Corp, reports disposition of shares to cover tax obligations and acquisition of shares through an employee stock purchase plan.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports disposals of common stock to cover tax obligations related to vesting restricted stock units.

Christopher Simon, President & CEO of Haemonetics Corp, reported disposing of shares to cover tax obligations related to vesting restricted stock units.

EVP and Chief Financial Officer of Haemonetics Corp, James D'Arecca, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Roy Galvin, President, Global Plasma & BC at Haemonetics Corp, reports disposition of shares to cover tax obligations and acquisition of shares through an employee stock purchase plan.

Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Haemonetics CEO Christopher Simon transferred 39,704 shares of company stock to a family trust in exchange for cash, according to a recent SEC filing.

Stewart W. Strong, President of Global Hospital at Haemonetics Corp, sold 4,312 shares of common stock at $91.15 per share on July 26, 2024, under a pre-existing 10b5-1 trading plan.

Stewart W. Strong, President of Global Hospital at Haemonetics Corp, reports acquisition of shares from performance share units and subsequent disposal for tax obligations.

Director Robert E. Abernathy acquired 2,207 shares of Haemonetics Corp common stock in the form of restricted stock units, vesting on the first anniversary of the grant date.

Director Diane M. Bryant reports acquisition of 2,207 restricted stock units (RSUs) of Haemonetics Corp.

Director Michael J. Coyle reports acquisition of 2,207 restricted stock units (RSUs) of Haemonetics Corp.

Director Charles J Dockendorff reports acquisition of 2,207 restricted stock units of Haemonetics Corp.